Corcept Therapeutics Incorporated (CORT)

NCM – Real Time Price. Currency in USD

51.16

-0.04 (-0.08%)

At close: May 12, 2026, 4:00 PM EDT

52.42

+1.26 (2.46%)

After-hours: May 12, 2026, 7:50 PM EDT

04.05.2026

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.

01.05.2026

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.

01.05.2026

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.

01.05.2026

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

01.05.2026

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.

23.04.2026

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access.

21.04.2026

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

NEW YORK, April 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline. So what: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Videos

No Data

There is no data to display

Press releases

21.04.2026

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Corcept Therapeutics Incorporated (CORT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Corcept Therapeutics Incorporated (CORT)

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Videos

No Data

Press releases

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Videos

No Data

Press releases

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

Search stocks

Corcept Therapeutics Incorporated (CORT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Corcept Therapeutics Incorporated (CORT)

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Videos

No Data

Press releases

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

Videos

No Data

Press releases

Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit

CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT

Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm